CRSP
CRISPR Therapeutics AG
NASDAQ · Healthcare · Biotechnology · CH
$55.79
−1.24%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−8.4x
Market Cap
$5.39B
MomentumView details →
1D Return
−1.24%
YTD Return
+5.91%
RSI (14)
50.0
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−8.4x
Market Cap
$5.39B
RSI (14)
50.0
MomentumView details →
1D Return
−1.24%
YTD Return
+5.91%
SummaryUpdated Jun 1, 2026
CRISPR Therapeutics AG (NASDAQ:CRSP) is a Swiss-based gene editing company founded in 2013 that develops gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform technology. The company went public in October 2016 and has emerged as one of the leading players in the rapidly evolving field of gene editing therapeutics. CRISPR Therapeutics focuses on creating treatments for conditions ranging from blood disorders to cancer and diabetes, with its lead therapy CTX001 representing one of the first CRISPR-based treatments to advance through clinical trials toward potential regulatory approval.
Similar companies
Latest newsMore news →
Bank of America Corp DE reduced its stake in CRISPR Therapeutics AG by 10.4% during the first quarter, selling 113,815 shares and retaining 983,072 shares, as disclosed in a recent SEC filing.23d agoCRISPR Therapeutics AG elected Samarth Kulkarni as Chairman of the Board of Directors and Ali Behbahani, Maria Fardis, H. Edward Fleming Jr., and Simeon J. George as members of the Board of Directors, effective June 4, 2026.93d ago